[HTML][HTML] GLP-1 receptor agonists in the treatment of type 2 diabetes–state-of-the-art
MA Nauck, DR Quast, J Wefers, JJ Meier - Molecular metabolism, 2021 - Elsevier
Background GLP-1 receptor agonists (GLP-1 RAs) with exenatide bid first approved to treat
type 2 diabetes in 2005 have been further developed to yield effective compounds …
type 2 diabetes in 2005 have been further developed to yield effective compounds …
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
JR Ussher, DJ Drucker - Nature Reviews Cardiology, 2023 - nature.com
Type 2 diabetes mellitus (T2DM) and obesity are metabolic disorders characterized by
excess cardiovascular risk. Glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists …
excess cardiovascular risk. Glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists …
The discovery and development of liraglutide and semaglutide
LB Knudsen, J Lau - Frontiers in endocrinology, 2019 - frontiersin.org
The discovery of glucagon-like peptide-1 (GLP-1), an incretin hormone with important effects
on glycemic control and body weight regulation, led to efforts to extend its half-life and make …
on glycemic control and body weight regulation, led to efforts to extend its half-life and make …
The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE−/− and LDLr−/− Mice by a Mechanism That Includes Inflammatory Pathways
G Rakipovski, B Rolin, J Nøhr, I Klewe… - JACC: Basic to …, 2018 - jacc.org
The glucagon-like peptide-1 receptor agonists (GLP-1RAs) liraglutide and semaglutide
reduce cardiovascular risk in type 2 diabetes patients. The mode of action is suggested to …
reduce cardiovascular risk in type 2 diabetes patients. The mode of action is suggested to …
The postprandial actions of GLP-1 receptor agonists: the missing link for cardiovascular and kidney protection in type 2 diabetes
Recent clinical trials in people with type 2 diabetes have demonstrated beneficial actions on
heart and kidney outcomes following treatment with GLP-1RAs. In part, these actions are …
heart and kidney outcomes following treatment with GLP-1RAs. In part, these actions are …
GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
Patients with type 2 diabetes (T2DM) have a substantial risk of develo** cardiovascular
disease. The strong connection between the severity of hyperglycaemia, metabolic changes …
disease. The strong connection between the severity of hyperglycaemia, metabolic changes …
Coronary microvascular dysfunction in diabetes mellitus: pathogenetic mechanisms and potential therapeutic options
T Salvatore, R Galiero, A Caturano, E Vetrano… - Biomedicines, 2022 - mdpi.com
Diabetic patients are frequently affected by coronary microvascular dysfunction (CMD), a
condition consisting of a combination of altered vasomotion and long-term structural change …
condition consisting of a combination of altered vasomotion and long-term structural change …
Cardiovascular and renal effectiveness of GLP-1 receptor agonists vs. other glucose-lowering drugs in type 2 diabetes: a systematic review and meta-analysis of real …
I Caruso, A Cignarelli, GP Sorice, A Natalicchio… - Metabolites, 2022 - mdpi.com
Cardiovascular outcome trials (CVOT) showed that treatment with glucagon-like peptide-1
receptor agonists (GLP-1RA) is associated with significant cardiovascular benefits …
receptor agonists (GLP-1RA) is associated with significant cardiovascular benefits …
Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study
S Piccini, G Favacchio, C Panico, E Morenghi… - Cardiovascular …, 2023 - Springer
Background Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown
cardiovascular benefits in cardiovascular outcome trials in type 2 diabetes mellitus …
cardiovascular benefits in cardiovascular outcome trials in type 2 diabetes mellitus …
Cardiovascular safety and benefits of semaglutide in patients with type 2 diabetes: findings from SUSTAIN 6 and PIONEER 6
MA Nauck, DR Quast - Frontiers in endocrinology, 2021 - frontiersin.org
To exclude an excess risk of cardiovascular (CV) events, CV outcomes trials (CVOTs) have
assessed the effects of new glucose-lowering therapies, including glucagon-like peptide-1 …
assessed the effects of new glucose-lowering therapies, including glucagon-like peptide-1 …